FIG 3.

ROC curve of objective response enrichment by DLL3 expression. ROC curve reflecting true-positive rate and false-positive rate of enrichment of objective response when FIH patients (1-100 mg cohorts) are retrospectively examined for selection using DLL3 expression assessed with the Ventana SP347 assay. ROC analysis included 77 patients enrolled in the 1-100 mg cohorts for whom pretreatment DLL3 expression readouts were available. DLL3, delta-like ligand 3; FIH, first-in-human; ROC, receiver operating characteristic.